![Australia Stock Market Today 23/08/2026 [UPDATE: 08:38 AEST] [Healthcare Surge: Weekly Recap and Week Ahead]](https://ts2.tech/wp-content/uploads/2026/08/AU-market-dashboard-2026-08-23-0843.jpg "Australia Stock Market Today 23/08/2026 [UPDATE: 08:38 AEST] [Healthcare Surge: Weekly Recap and Week Ahead]")
Australia Stock Market Today 23/08/2026 [UPDATE: 08:38 AEST] [Healthcare Surge: Weekly Recap and Week Ahead]
Healthcare Surge: Weekly Recap and Week Ahead23/08/2026 · 08:38 AEST WEEKLY RECAP + WEEK AHEAD Healthcare broke away from a softer ASX CSL's reset-year result powered a sharp sector rotation. Banks and consumer names…
WEEKLY RECAP + WEEK AHEAD
Healthcare broke away from a softer ASX
CSL's reset-year result powered a sharp sector rotation. Banks and consumer names carried the downside; inflation and a dense earnings slate now set the next test.
ASX CASH MARKET CLOSED
Sunday non-trading day
Dashboard updated: 23 Aug 2026, 08:43 AEST (UTC+10)
Market data: latest close, 21 Aug 2026, about 16:10 AEST
Week in one frame
Index dataWeekly changes compare the 21 Aug close with 14 Aug. Sector figures are calculated from published closes and may differ slightly from vendor summaries.
What drove it
CSL FY26- CSL reset: US$3.1bn underlying NPATA, US$3.5bn operating cash flow and about 5% FY27 underlying NPAT growth guidance outweighed a US$2.6bn statutory loss after US$7.1bn of impairments.
- Banks reversed: financials fell about 5.1% over the week; CBA alone lost 5.15%, making the index's defensive healthcare surge look even more concentrated.
- Friday split: GYG jumped 11.5% after a 29.7% profit increase, while Zip fell 14.4%, Telix 10.1% and Super Retail 7.5%.
- Oil risk: Brent finished near US$93.49/bbl on Friday. The Iran risk premium helped energy but revived inflation and bond-yield concerns.
Week ahead
Scheduled events - AEST (UTC+10)ASX reopens
Opening single-price auction from 09:59; continuous trading follows. Results include Bendigo Bank, Ampol, Endeavour, PLS and Reece.
RBA minutes - 11:30
David Jacobs speaks at 14:00. Coles, Woodside, Scentre and Viva Energy are scheduled to report.
July CPI - 11:30
June CPI was 3.8% y/y and trimmed mean 3.6% y/y. Domino's, Flight Centre and Lynas are among the scheduled results.
Capex + RBA Bulletin - 11:30
Private capital expenditure and the RBA Bulletin land together; reporting season remains active.
Bull case
CSL's rebound broadens into health care and CPI eases enough to cap yields. Holding 9,000 while breadth improves would support a rotation-led recovery.
Bear case
Sticky CPI, firm oil and a 10-year yield above 5% pressure bank, property and consumer multiples while earnings misses spread beyond isolated names.
Watch first
ASX 200: 9,000 support, then 9,115 resistance. Also watch financial-sector stabilisation, AUD/USD 0.71 and whether VIX stays near 10.5.
Telix Pharmaceuticals trails ASX 200 by 8.3 points; Japan remains beyond guidance
Telix Pharmaceuticals Ltd opened Monday trading at A$14.91, its last available price. Shares dropped 4.48% on Friday. Australia's cash market was active, though Google Finance continued to display Friday’s data.
Australia Stock Market Today: ASX 200 Ends Lower but Still Logs Best Week Since 2022
Australian shares finished in the red on Friday, but the benchmark still managed its best weekly showing since late 2022. A possible U.S.-Iran truce helped the week’s relief rally hold. The S&P/ASX 200 gave up 12.6 points, or 0.14%, to close at 8,960.6. BHP dropped 1.1%, Fortescue lost 1.3%, and Santos slipped 0.6%.
Telix (ASX:TLX) share price jumps 14% on 2026 revenue outlook — what moved the stock
Telix Pharmaceuticals Limited surged 14.2% Friday, wrapping up at A$10.43 after swinging between A$9.49 and A$10.78, according to Google Finance. Even with that pop, shares remain far from the 52-week peak of A$31.97.
Telix Pharmaceuticals share price jumps 8% on ASX:TLX as JPMorgan crosses 5% — what to watch next
Telix Pharmaceuticals Ltd shares grabbed attention ahead of the Australian open, closing Tuesday up 8.31% at A$11.86. The jump came after the company filed a fresh “substantial holder” notice with the exchange.
Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing
Telix Pharmaceuticals shares dropped 7.7% on Wednesday, settling at A$10.61. The decline came as investors digested a new quarterly update alongside a regulatory move in China related to its prostate cancer imaging business.
Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts
Telix Pharmaceuticals Limited entered the spotlight again on December 17, 2025, as TLX stock extended its December sell-off amid a fast-moving mix of clinical-trial updates, regulatory overhang, and investor litigation headlines. Telix Pharmaceuticals+2Investing.com+2
Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook
Telix Pharmaceuticals Limited is ending 2025 in a paradoxical position: commercially successful, rich in late‑stage oncology assets, but trading near its 12‑month lows amid SEC scrutiny, an FDA setback and a growing stack of class‑action lawsuits. At the same time, new clinical milestones and a fresh collaboration with Varian are reinforcing the long‑term radiopharmaceutical growth story.
TechStock² Updates
